Color Health launches its first product to help make healthcare more affordable, accessible, and actionable.

In 2015, Color launched with a new clinical genetic testing model to help patients understand and take action on their personal risk of cancer. Our first product tested for BRCA1, BRCA2, and 17 other genes that increase an individual’s cancer risk. At the time, genetic tests for ovarian and breast cancer risk typically cost several thousand dollars, and access was often gated through long wait times for genetic counseling appointments at centers of excellence. Color was the first to deliver comprehensive genetic testing—including genetic counseling, at-home sample collection, and easy-to-understand reports—for less than a tenth of the cost. This affordable model has helped hundreds of thousands of individuals take action on their genetic risk.

Learn how Color worked with the Teamsters Health and Welfare Fund of Philadelphia and Vicinity to change how employees engaged with preventive care by better understanding their risk of cancer and other genetic diseases.

Color begins a long history of partnering with leaders in research and precision medicine, including the National Institutes of Health.

In 2018, the National Institutes of Health (NIH) awarded funding to Color, in partnership with the Broad Institute of MIT and Harvard, to establish one of three genome centers for its historic All of Us Research Program, a one million-participant program aimed at helping researchers better understand long-term health outcomes across the U.S. Color was initially selected to analyze and report genomic data for a set of 59 genes that cause conditions such as breast and ovarian cancer, hypercholesterolemia, Lynch syndrome, and more. As one of three Clinical Validation Laboratories and the sole provider of genetic counseling, Color helped deliver research and clinical genetic testing return of results at national scale.

Over time, the program gathered data from hundreds of thousands of participants, over 80% of whom come from populations that have been historically underrepresented in clinical research. Our work with the NIH was the largest of our major research collaborations to that point. We have since gone on to work with research institutions such as the Mayo Clinic, the Fred Hutchinson Cancer Research Center, and the University of Chicago and many local, state, and Federal governments.

Learn about an important NIH and Color partnership milestone—processing 100,000 genetic results for the All of Us Program—below.

Color mobilized to change access to critical COVID-19 testing, vaccination, and treatment services.

On March 16th, 2020, the first stay-at-home orders were issued in the San Francisco Bay Area. Exactly two weeks later, Color had built a CLIA-certified COVID-19 testing lab and digital platform. One week after that, Color and the City and County of San Francisco launched one of the first high-capacity, public COVID testing sites.

In the months and years to come, Color supported employers, schools, and Federal, state, and local health departments across the country—Thermo Fisher Scientific, the CDC, the State of California and the Commonwealth of Massachusetts, Chicago Public Schools, to name a few—to provide critical access where people worked, played, learned, and worshiped. When antiviral treatment became available, Color ran three-quarters of the country’s state-level telehealth programs, with prescription delivery within 24 to 48 hours of symptom onset. Our population health work has since expanded to support other infectious disease areas. Color currently runs the State of California’s HIV PrEP telehealth access program.

Over the years, we continued to invest in access—offering multilingual support, flexible care delivery models, hotlines for those without smartphones or computers, and more— which further cemented our commitment to broad population health.

Color partnered with the American Cancer Society to operationalize a joint mission of ending cancer as we know it.

In June 2023, Color and the American Cancer Society (ACS) introduced a cancer screening and prevention program for employers and labor organizations, combining the ACS’s expertise in cancer screening, prevention, and risk reduction with Color’s leadership in population-scale healthcare delivery.

Rates of cancer screening, stage of detection, and treatment outcomes reflect some of the deepest disparities in American healthcare. With 159 million Americans receiving healthcare coverage through their employer, the ACS and Color recognized the critical role employers play in removing barriers of access to timely and quality preventive care.

Color’s cancer care solution takes hold with employers, as the team joins forces with Hasbro, Shoestring Holdings, and more.

Since that time, our day-in, day-out focus has been on helping employers, health plans, labor and public sector reshape their strategies and take control of cancer outcomes and costs. Our program has continued to expand to support early detection, 100% follow up on abnormal screenings, diagnosis review, cancer treatment management, and survivorship care. Through our Virtual Cancer Clinic, Color  helps employees and members diagnose cancer at an earlier stage, identify a diagnosis at the earliest treatable stage; care for patients going through their diagnostic journeys with empathy and speed, and help cancer survivors navigate return-to-work challenges.

See this case study from Hasbro and how Color is supporting their strategy to take control of cancer outcomes and costs.

We reinvented cancer care to deliver when it matters most.

In 2025, Color advanced its mission to deliver faster, more connected, and more expert-led cancer care for people across the entire cancer journey. Our oncologist-led Virtual Cancer Clinic continued to challenge the assumptions of a system that remains too slow and too fragmented for the realities of cancer today. By focusing on speed, access, and direct clinical care, we helped reduce uncertainty for patients, eased pressure on families, and gave organizations a more effective way to support their populations.

Throughout 2025, Color delivered care that met people wherever they were in their journey. We provided earlier answers through proactive outreach and comprehensive clinical assessment, accelerated time to diagnosis, and offered specialist guidance at the high-stakes moments when decisions matter most. Our care teams stayed closely connected to patients during active treatment, offering support and reassurance through some of the hardest moments of the experience, and intervening early to prevent complications, reduce emergency visits, and keep people on their treatment path. Survivors received structured screening plans and whole-person follow up to support long-term health, reduce recurrence risk, and create a more stable transition back to life and work.

The impact of this work was clear. In 2025, Color improved screening adherence, closed care gaps, accelerated time to active treatment, and delivered measurable savings for employers, unions, public-sector organizations, and health plans. Most importantly, people received care that felt more responsive, more personal, and more supportive than what the traditional system often provides. As we look ahead, our mission remains unchanged: to deliver a model of cancer care that brings clarity, expertise, and timely action to every person who needs it.